169 related articles for article (PubMed ID: 36905576)
1. Neutrophil-to-lymphocyte ratio as an independent factor for worse prognosis in radioiodine refractory thyroid cancer patients.
Treistman N; Cavalcante LBCP; Gonzalez F; Fernandes PIW; de Andrade FA; Garcis Alves-Junior PA; Corbo R; Bulzico DA; Vaisman F
Endocrine; 2023 Jul; 81(1):141-148. PubMed ID: 36905576
[TBL] [Abstract][Full Text] [Related]
2. Clinical role of 18F-FDG PET/CT for detection of radioactive iodine refractory differentiated thyroid cancer.
Tang X; Shi L; Zhao Z; Wang J; Yang R; Huang Y; Tang J; Chen Z; Wang F
Medicine (Baltimore); 2023 Jun; 102(24):e33878. PubMed ID: 37327310
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer.
Manohar PM; Beesley LJ; Bellile EL; Worden FP; Avram AM
Clin Nucl Med; 2018 Sep; 43(9):641-647. PubMed ID: 30015659
[TBL] [Abstract][Full Text] [Related]
4.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
5. Incorporation of the SUVmax Measured From FDG PET and Neutrophil-to-lymphocyte Ratio Improves Prediction of Clinical Outcomes in Patients With Locally Advanced Non-small-cell Lung Cancer.
Guo D; Jin F; Jing W; Li M; Chen D; Zou B; Jiang G; Fu L; Zhu H; Kong L; Wu J; Yu J; Yue J
Clin Lung Cancer; 2019 Nov; 20(6):412-419. PubMed ID: 31300364
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory biomarkers predict outcomes of patients with radioactive iodine refractory thyroid cancer treated with sorafenib.
Jin M; Kim M; Jeon MJ; Kim EY; Shin DY; Kim BH; Kim WB; Shong YK; Lim DJ; Kim WG
Endocrine; 2023 Aug; 81(2):298-305. PubMed ID: 36928602
[TBL] [Abstract][Full Text] [Related]
7. PET response assessment in apatinib-treated radioactive iodine-refractory thyroid cancer.
Wang C; Zhang X; Yang X; Li H; Cui R; Guan W; Li X; Zhu Z; Lin Y
Endocr Relat Cancer; 2018 Jun; 25(6):653-663. PubMed ID: 29618578
[TBL] [Abstract][Full Text] [Related]
8. Sequential Analysis of Neutrophil-to-lymphocyte Ratio for Differentiated Thyroid Cancer Patients Treated With Lenvatinib.
Fukuda N; Wang X; Ohmoto A; Urasaki T; Sato Y; Nakano K; Nishizawa M; Yunokawa M; Ono M; Tomomatsu J; Takahashi S
In Vivo; 2020; 34(2):709-714. PubMed ID: 32111774
[TBL] [Abstract][Full Text] [Related]
9. Utility of FDG PET at the Initial Radioiodine Therapy in Differentiated Thyroid Cancer.
Matsuo M; Baba S; Hashimoto K; Isoda T; Kitamura Y; Kogo R; Jiromaru R; Hongo T; Manako T; Nakagawa T
Anticancer Res; 2023 Jan; 43(1):183-190. PubMed ID: 36585178
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib.
Kim CA; Kim M; Jin M; Kim HK; Jeon MJ; Lim DJ; Kim BH; Kang HC; Kim WB; Shin DY; Kim WG
Endocrinol Metab (Seoul); 2024 Apr; 39(2):334-343. PubMed ID: 38572536
[TBL] [Abstract][Full Text] [Related]
11. Impact of age on survival in radioiodine refractory differentiated thyroid cancer patients.
Saïe C; Wassermann J; Mathy E; Chereau N; Leenhardt L; Tezenas du Montcel S; Buffet C
Eur J Endocrinol; 2021 May; 184(5):667-676. PubMed ID: 33667193
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological features of differentiated thyroid carcinoma as predictors of the effects of radioactive iodine therapy.
Liu W; Jiang B; Xue J; Liu R; Wei Y; Li P
Ann Diagn Pathol; 2024 Apr; 69():152243. PubMed ID: 38128440
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET-CT metabolic parameters in small cell lung cancer (SCLC).
Mirili C; Guney IB; Paydas S; Seydaoglu G; Kapukaya TK; Ogul A; Gokcay S; Buyuksimsek M; Yetisir AE; Karaalioglu B; Tohumcuoglu M
Int J Clin Oncol; 2019 Feb; 24(2):168-178. PubMed ID: 30109543
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the usefulness of positron emission tomography with [18F]fluorodeoxylglucose performed to detect non-radioiodine avid recurrence and/or metastasis of differentiated thyroid cancer - a preliminary study.
Kolodziej M; Saracyn M; Lubas A; Brodowska-Kania D; Mazurek A; Dziuk M; Dymus J; Kaminski G
Nucl Med Rev Cent East Eur; 2021; 24(2):63-69. PubMed ID: 34382670
[TBL] [Abstract][Full Text] [Related]
15. Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC).
Shi L; You Q; Wang J; Wang H; Li S; Tian R; Yao X; Wu W; Zhang L; Wang F; Lin Y; Li S
Endocrine; 2022 Oct; 78(1):68-76. PubMed ID: 35767182
[TBL] [Abstract][Full Text] [Related]
16. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Shobab L; Gomes-Lima C; Zeymo A; Feldman R; Jonklaas J; Wartofsky L; Burman KD
Thyroid; 2019 Sep; 29(9):1262-1268. PubMed ID: 31319763
[No Abstract] [Full Text] [Related]
17. Progression free survival related to
Zhu X; Wu S; Yuan X; Wang H; Ma C
Hell J Nucl Med; 2019; 22(2):123-130. PubMed ID: 31273354
[TBL] [Abstract][Full Text] [Related]
18. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial.
Lin YS; Yang H; Ding Y; Cheng YZ; Shi F; Tan J; Deng ZY; Chen ZD; Wang RF; Ji QH; Huang R; Li LF
Thyroid; 2021 Apr; 31(4):607-615. PubMed ID: 32907500
[No Abstract] [Full Text] [Related]
19. 18F-FDG PET/CT concurrent with first radioiodine post-therapeutic scan in high risk differentiated thyroid cancer: a useful tool or just an expensive diversion?
Rizzo A; Perotti G; Zagaria L; Lanni V; Racca M; Palestini N; Salvatori M
Q J Nucl Med Mol Imaging; 2023 Jun; 67(2):158-166. PubMed ID: 35238517
[TBL] [Abstract][Full Text] [Related]
20. ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.
Rosenbaum-Krumme SJ; Görges R; Bockisch A; Binse I
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1373-80. PubMed ID: 22718304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
